The content on this site is intended for healthcare professionals only
Dr Tomonori Mizutani speaks to ecancer at the SIOG 2019 meeting in Geneva about JCOG, the Japan Clinical Oncology Group.
The Japan Clinical Oncology Group (JCOG)'s mission is to establish and advance standard treatments for various types of cancers.
They conduct a variety of multi-center, multi-disciplinary phase II or phase III trials that combine various modalities such as drugs, surgery, radiotherapy, and endoscopy.
Dr Mizutani explains how JCOG will be changing the scene of geriatric oncology in Japan, and how putting the geriatric assessment to use in Japan will streamline this process.
Dr Mizutani wants to put an end to and age-based discrimination in the Japanese healthcare system.
This service has been kindly supported by unrestricted grants from Janssen Oncology and Sanofi Genzyme.
Prostate cancer
ESMO 2024: Best practice in HRRm testing in patients with metastatic prostate cancer
Feasibility and safety of boost at 74 Gy based on interim FDG-PET during thoracic radio-chemotherapy for NSCLC patients
Adjuvant radiotherapy has no benefit following radical prostatectomy
Short-course radiation as effective as standard treatment for breast cancer patients choosing reconstruction after mastectomy
TARGeted IORT INTRABEAM is a useful treatment option for early stage breast cancer
TARGIT-E: Intraoperative Radiotherapy (IORT) in elderly patients with small breast cancer
The advantages of IORT for early breast cancer treatment
Durable effect of imatinib and metronomic chemotherapy with capecitabine in pancreatic carcinoma
